Sanofi poised for explosive growth in global dermatology market

28th June 2017 (Last Updated June 28th, 2017 09:35)

Over the next few years Sanofi will go from being an also-ran in the dermatology arena to being a major player, thanks to the performance of a groundbreaking new drug.

Sanofi poised for explosive growth in global dermatology market

In 2016 Sanofi only had two commercially significant marketed products for skin diseases – Allegra and Targocid – which generated $31m and $8m respectively.

These modest revenues meant the company commanded a market share of just 0.27%, which made it the 25th placed company in the therapy area.

However, between 2016 and 2023 Sanofi’s revenue from dermatology is forecast to increase at a compound annual growth rate (CAGR) of 83.6%, peaking at $2.8 billion in 2023.

This will make it the fourth largest company in the therapy area, with a market share of 10.3%.

Growth driven by Dupixent

graph

In March 2017 Sanofi received FDA approval for Dupixent – the first biologic drug to treat moderate-to-severe atopic dermatitis.

It will be marketed by Sanofi and Regeneron, with the majority of the revenue going to Sanofi.

In 2017 Sanofi is forecast to generate $102 million from Dupixent, and between 2017 and 2023 this will increase at a CAGR of 154%, peaking at $2.75 billion in 2023.

With Sanofi’s and Regeneron’s 2023 Dupixent revenues combined, the drug will be the second most commercially successful product in dermatology, with an annual revenue of $3.6 billion, trailing behind only Novartis’s Cosentyx.